Secukinumab, trade name Cosentyx, is a human monoclonal antibody that binds to the protein interleukin (IL)-17A,and is manufactured by Novartis Pharma AG for the treatment of psoriasis. The drug is also being investigated as a treatment for uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It targets member A form of the cytokine family of interleukin 17, severely inhibiting its functioning. It is highly specific to the human immunoglobulin G1k (IgG1k) subclass. On January 21, 2015, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis.